Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1491-1500 of 7972

  • Results filtered:
  • Locations: Rochester, MN
Edit search filters
  1. RECOVER-ENERGIZE Platform Protocol

    Rochester, MN

  2. Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

    Eau Claire, WI, La Crosse, WI, Mankato, MN, Rochester, MN, Jacksonville, FL

  3. Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

    Rochester, MN

  4. Acoramidis Transthyretin Amyloidosis Prevention Trial In The Young (ACT-EARLY) Study In Asymptomatic Carriers Of A Pathogenic TTR Variant

    Rochester, MN

  5. A Study to Evaluate Mesenchymal Stem Cells to Treat Multiple System Atrophy

    Rochester, MN

  6. Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

    Rochester, MN

  8. A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)

    Rochester, MN, Jacksonville, FL

  9. A Study to Evaluate the Safety and Effectiveness of Hypofractionation Proton Beam Therapy in Patients with Clinically Localized, Intermediate, or High Risk Prostate Cancer

    Rochester, MN, Scottsdale/Phoenix, AZ

  10. Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer